FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003100404> ?p ?o ?g. }

• W2003100404 endingPage "A129" @default.
• W2003100404 startingPage "A128.2" @default.
• W2003100404 abstract "<h3>Background</h3> Topical intranasal steroids are widely considered to be the most efficacious pharmacotherapy for the treatment of allergic rhinitis, and yet, for many, symptoms still remain troublesome. We hypothesise that the residual symptoms are a result of nasal neuronal hyperresponsiveness during the pollen season and should be ameliorated by a topical intranasal TRPV1 antagonist. SB705498 is a selective TRPV1 antagonist shown to produce significant inhibition in animal and human models involving nasal sensory nerves. <h3>Methods</h3> The study involved 70, male and female, subjects with proven rhinitis in a randomised, double-blind, placebo-controlled, 3-way incomplete block crossover design in a well validated Allergen Challenge Chamber paradigm in Vienna. Subjects received Placebo, FP (200ug), SB705498 (12mg), or FP+498. Subjects were dosed for 8 days, within the pollen season, before being exposed to a chamber challenge on the 8th day. TNSS was the primary endpoint recorded for the 4 hours in the chamber. The comparisons of interest were FP+498 vs. FP, and 498 vs. Placebo. Additional endpoints consisted of symptoms over the 8 days of dosing, Active Anterior Rhinomanometry, Rhinoconjunctivitis QLQ, PK and tolerability. Each period was separated by 14–20 days. <h3>Results</h3> There was no evidence of a decrease in symptoms with FP+498 compared to FP alone, or for 498 compared to placebo. Statistically significant and clinically relevant reductions in TNSS compared with Placebo were observed at all time points during the challenge for FP and FP+498. The mean (95% CI) reduction in weighted mean TNSS was –2.94 (–3.38, –2.50) for FP alone and-2.28 (–2.79, –1.78) for the combination. There was no positive impact over FP, or 498 over Placebo, for Diary Card symptoms, RQLQ or Nasal Airflow. Tmax occurred at approximately 5 hrs post dose, in keeping with previous studies. SB705498 was very well tolerated. <h3>Conclusions</h3> In a robust clinical model of allergic rhinitis, there was no intrinsic activity demonstrated by SB705498 and no additive effect on a background of intranasal steroids. FP was highly effective in this study. We conclude that despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways." @default.
• W2003100404 created "2016-06-24" @default.
• W2003100404 creator A5000684531 @default.
• W2003100404 creator A5067875135 @default.
• W2003100404 creator A5068824951 @default.
• W2003100404 creator A5080853957 @default.
• W2003100404 creator A5091287615 @default.
• W2003100404 date "2012-11-19" @default.
• W2003100404 modified "2023-09-27" @default.
• W2003100404 title "P153 The impact of TRPV1 Antagonism on the Treatment of Seasonal Allergic Rhinitis" @default.
• W2003100404 doi "https://doi.org/10.1136/thoraxjnl-2012-202678.214" @default.
• W2003100404 hasPublicationYear "2012" @default.
• W2003100404 type Work @default.
• W2003100404 sameAs 2003100404 @default.
• W2003100404 citedByCount "0" @default.
• W2003100404 crossrefType "journal-article" @default.
• W2003100404 hasAuthorship W2003100404A5000684531 @default.
• W2003100404 hasAuthorship W2003100404A5067875135 @default.
• W2003100404 hasAuthorship W2003100404A5068824951 @default.
• W2003100404 hasAuthorship W2003100404A5080853957 @default.
• W2003100404 hasAuthorship W2003100404A5091287615 @default.
• W2003100404 hasBestOaLocation W20031004041 @default.
• W2003100404 hasConcept C126322002 @default.
• W2003100404 hasConcept C142724271 @default.
• W2003100404 hasConcept C170493617 @default.
• W2003100404 hasConcept C197934379 @default.
• W2003100404 hasConcept C204787440 @default.
• W2003100404 hasConcept C27081682 @default.
• W2003100404 hasConcept C2776885963 @default.
• W2003100404 hasConcept C2777288759 @default.
• W2003100404 hasConcept C2778375690 @default.
• W2003100404 hasConcept C42219234 @default.
• W2003100404 hasConcept C71924100 @default.
• W2003100404 hasConcept C85663871 @default.
• W2003100404 hasConcept C87813604 @default.
• W2003100404 hasConcept C98274493 @default.
• W2003100404 hasConceptScore W2003100404C126322002 @default.
• W2003100404 hasConceptScore W2003100404C142724271 @default.
• W2003100404 hasConceptScore W2003100404C170493617 @default.
• W2003100404 hasConceptScore W2003100404C197934379 @default.
• W2003100404 hasConceptScore W2003100404C204787440 @default.
• W2003100404 hasConceptScore W2003100404C27081682 @default.
• W2003100404 hasConceptScore W2003100404C2776885963 @default.
• W2003100404 hasConceptScore W2003100404C2777288759 @default.
• W2003100404 hasConceptScore W2003100404C2778375690 @default.
• W2003100404 hasConceptScore W2003100404C42219234 @default.
• W2003100404 hasConceptScore W2003100404C71924100 @default.
• W2003100404 hasConceptScore W2003100404C85663871 @default.
• W2003100404 hasConceptScore W2003100404C87813604 @default.
• W2003100404 hasConceptScore W2003100404C98274493 @default.
• W2003100404 hasIssue "Suppl 2" @default.
• W2003100404 hasLocation W20031004041 @default.
• W2003100404 hasOpenAccess W2003100404 @default.
• W2003100404 hasPrimaryLocation W20031004041 @default.
• W2003100404 hasRelatedWork W1967648137 @default.
• W2003100404 hasRelatedWork W1978528922 @default.
• W2003100404 hasRelatedWork W2058596886 @default.
• W2003100404 hasRelatedWork W2068849886 @default.
• W2003100404 hasRelatedWork W2073867197 @default.
• W2003100404 hasRelatedWork W2110917813 @default.
• W2003100404 hasRelatedWork W2807575822 @default.
• W2003100404 hasRelatedWork W2897284151 @default.
• W2003100404 hasRelatedWork W3128674126 @default.
• W2003100404 hasRelatedWork W4316362651 @default.
• W2003100404 hasVolume "67" @default.
• W2003100404 isParatext "false" @default.
• W2003100404 isRetracted "false" @default.
• W2003100404 magId "2003100404" @default.
• W2003100404 workType "article" @default.